10-Q: Champions Oncology Reports Strong Q3 2025 Results, Revenue Surges 41.8%

Champions Oncology's Q3 2025 revenue increased by 41.8% year-over-year, driven by growth in pharmacology services and data license sales.

Summary

• Champions Oncology reported a significant increase in revenue for the third quarter of fiscal year 2025, with a 41.8% increase compared to the same period in the previous year.
• The company's oncology revenue reached $17.039 million for the three months ended January 31, 2025, up from $12.019 million in 2024.
• For the nine months ended January 31, 2025, revenue totaled $44.589 million, a 23.3% increase from $36.153 million in the prior year.
• The increase in revenue was primarily driven by a stronger bookings to revenue conversion rate and sales of data licenses.
• The company reported net income of $4.495 million for the three months ended January 31, 2025, compared to a net loss of $2.530 million for the same period in 2024.
• Net income for the nine months ended January 31, 2025, was $6.536 million, compared to a net loss of $7.167 million for the same period in 2024.
• Basic net income per share was $0.33 for the quarter and $0.48 for the nine-month period.
• The company's cash and cash equivalents totaled $3.202 million as of January 31, 2025, compared to $2.618 million as of April 30, 2024.
• The company acknowledges a history of net losses, working capital deficits, and an accumulated deficit of $78.1 million as of January 31, 2025, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While the company shows strong revenue growth and a return to profitability, concerns about its ability to continue as a going concern and the potential need for a capital raise temper the positive outlook.

Positives

• Significant revenue growth of 41.8% in Q3 2025 compared to Q3 2024.
• Return to profitability with net income of $4.495 million in Q3 2025, compared to a net loss in the same period last year.
• Increased cash and cash equivalents to $3.202 million.
• Operational improvements leading to better revenue conversion from bookings.
• Decrease in cost of oncology revenue by 15.7% for the three months ended January 31, 2025.
• Decrease in research and development expense by 21.4% for the three months ended January 31, 2025.
• Decrease in general and administrative expenses by 13.2% for the three months ended January 31, 2025.

Negatives

• The company has a working capital deficit and an accumulated deficit of $78.1 million as of January 31, 2025.
• The company acknowledges a history of net losses, working capital deficits, and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.
• The company may need to raise additional equity or debt capital in the near term to fund operations.

Risks

• The company's ability to continue as a going concern is uncertain due to its history of net losses and accumulated deficit.
• The company may need to raise additional capital, and there is no assurance that it will be successful in doing so.
• Economic uncertainty and volatility in the financial markets could adversely affect the company's results of operations.
• The company is subject to foreign exchange rate fluctuations in connection with its international operations.

Future Outlook

The company believes it has strategies to increase revenues and reduce costs, but there are no assurances that these efforts will be successful. The company may need to raise additional equity or debt capital in the near term.

Management Comments

• Operational improvements implemented throughout the year have enhanced execution efficiency, contributing to the improvement in the conversion percentage of bookings to revenue.

Industry Context

Champions Oncology operates in the technology-enabled research organization sector, providing services to pharmaceutical and biotechnology companies. The company's focus on personalized approaches to drug development and its TumorGraft Technology Platform position it within the growing market for precision medicine and oncology research solutions.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing the specific financial details of Champions Oncology's direct competitors.
• However, companies like Charles River Laboratories, WuXi AppTec, and ICON plc are major players in the broader contract research organization (CRO) market, which includes preclinical and clinical oncology research services.
• Champions Oncology's revenue growth of 41.8% in Q3 2025 is a strong performance compared to the average growth rates of larger CROs, but it's important to consider that Champions Oncology is a smaller company with a more specialized focus.
• The company's focus on PDX models and data-driven solutions differentiates it from some of the more traditional CROs.

Related Party Transactions

• During the three months ended January 31, 2025 and 2024, the Company recognized $0 and $9,000, respectively, for consulting services provided by an affiliate of a Board member, unrelated to his duty as a Board member.
• During the nine months ended January 31, 2025 and 2024, the Company recognized $12,000 and $27,000, respectively, for consulting services provided by an affiliate of a Board member, unrelated to his duty as a Board member.

Stakeholder Impact

• Shareholders: The strong revenue growth and return to profitability are positive for shareholders, but the going concern uncertainty and potential capital raise could be concerning.
• Employees: The company's performance could impact employee morale and job security.
• Customers: The company's continued operation is important for customers who rely on its services.
• Suppliers: The company's financial stability affects its ability to pay suppliers.

Next Steps

• The company will continue to focus on increasing revenues and reducing costs.
• The company will evaluate strategic options to create additional value from its drug discovery business.
• The company may need to raise additional equity or debt capital in the near term.

Key Dates